UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 449

Sortiert nach

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

International journal of molecular sciences, 2019-08, Vol.20 (15), p.3821

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting YAP in malignant pleural mesothelioma

Journal of cellular and molecular medicine, 2017-11, Vol.21 (11), p.2663-2676

2017

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma

Journal of cellular and molecular medicine, 2018-06, Vol.22 (6), p.3139-3148

2018

Link zum Volltext

Verfügbarkeit prüfen

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

Cancers, 2020-05, Vol.12 (6), p.1361

2020

Link zum Volltext

Verfügbarkeit prüfen

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Scientific reports, 2022-03, Vol.12 (1), p.4398-4398, Article 4398

2022

Link zum Volltext

Verfügbarkeit prüfen

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

BMC cancer, 2021-07, Vol.21 (1), p.1-859, Article 859

2021

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model

Journal of cellular and molecular medicine, 2018-06, Vol.22 (6), p.3073-3085

2018

Link zum Volltext

Verfügbarkeit prüfen

Rab11 collaborates E-cadherin to promote collective cell migration and indicates a poor prognosis in colorectal carcinoma

European journal of clinical investigation, 2016-12, Vol.46 (12), p.1002-1011

2016

Link zum Volltext

Verfügbarkeit prüfen

Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model

Oncology reports, 2019-08, Vol.42 (2), p.697-707

2019

Link zum Volltext

Verfügbarkeit prüfen

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Thoracic cancer, 2020-06, Vol.11 (6), p.1541-1549

2020

Link zum Volltext

Verfügbarkeit prüfen

Curcumin Inhibits Invasiveness and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Through Reducing Matrix Metalloproteinase 2, 9 and Modulating p53-E-Cadherin Pathway

Integrative cancer therapies, 2015-09, Vol.14 (5), p.484-490

2015

Link zum Volltext

Verfügbarkeit prüfen

Topical dicloxacillin solution wash for papulopustular eruptions and purpuric drug eruptions due to epidermal growth factor inhibitors

International journal of dermatology, 2021-07, Vol.60 (7), p.e278-e281

2021

Link zum Volltext

Verfügbarkeit prüfen

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Scientific reports, 2023-11, Vol.13 (1), p.20323-20323, Article 20323

2023

Link zum Volltext

Verfügbarkeit prüfen

Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma

Journal of cellular and molecular medicine, 2015-10, Vol.19 (10), p.2385-2396

2015

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Thoracic cancer, 2023-01, Vol.14 (1), p.12-23

2023

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Chemopreventive Effects of a Novel Combined Plant Extract Comprising Gallic Acid and Hesperidin on Colorectal Cancer

Current issues in molecular biology, 2023-06, Vol.45 (6), p.4908-4922

2023

Link zum Volltext

Verfügbarkeit prüfen

Inhibitory Effect and Mechanisms of an Anthocyanins- and Anthocyanidins-Rich Extract from Purple-Shoot Tea on Colorectal Carcinoma Cell Proliferation

Journal of agricultural and food chemistry, 2012-04, Vol.60 (14), p.3686-3692

2012

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Thoracic cancer, 2022-07, Vol.13 (13), p.1888-1897

2022

Link zum Volltext

Verfügbarkeit prüfen

Urinary cadmium concentration is associated with the severity and clinical outcomes of COVID-19: a bicenter observational cohort study

Environmental health, 2024-03, Vol.23 (1), p.29-29, Article 29

2024

Link zum Volltext

Verfügbarkeit prüfen

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Therapeutic advances in respiratory disease, 2022, Vol.16, p.175346662211327-17534666221132731

2022

Link zum Volltext

Verfügbarkeit prüfen

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma

Journal of the European Academy of Dermatology and Venereology, 2023-02, Vol.37 (2), p.328-339

2023

Link zum Volltext

Verfügbarkeit prüfen

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study

International journal of molecular sciences, 2022-09, Vol.23 (18), p.10661

2022

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Thoracic cancer, 2024-03, Vol.15 (7), p.529-537

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Cancers, 2022-01, Vol.14 (3), p.674

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

Cancers, 2022-02, Vol.14 (4), p.977

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 449

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(380)
Mit Volltextzugriff
(423)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Targeting YAP in malignant pleural mesothelioma

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model

Rab11 collaborates E-cadherin to promote collective cell migration and indicates a poor prognosis in colorectal carcinoma

Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Curcumin Inhibits Invasiveness and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Through Reducing Matrix Metalloproteinase 2, 9 and Modulating p53-E-Cadherin Pathway

Topical dicloxacillin solution wash for papulopustular eruptions and purpuric drug eruptions due to epidermal growth factor inhibitors

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Synergistic Chemopreventive Effects of a Novel Combined Plant Extract Comprising Gallic Acid and Hesperidin on Colorectal Cancer

Inhibitory Effect and Mechanisms of an Anthocyanins- and Anthocyanidins-Rich Extract from Purple-Shoot Tea on Colorectal Carcinoma Cell Proliferation

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Urinary cadmium concentration is associated with the severity and clinical outcomes of COVID-19: a bicenter observational cohort study

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

Suchergebnisse filtern